Literature DB >> 32422159

GRP78 and next generation cancer hallmarks: An underexplored molecular target in cancer chemoprevention research.

Shenbagam Madhavan1, Sangeetha Nagarajan2.   

Abstract

Glucose regulated protein 78 (GRP 78), a master regulator of endoplasmic reticulum stress has been reported to be up regulated in various cancers and remains a crucial link between tumor glycolysis and tumor microenvironment. Overexpressed GRP78 has also shown to induce immune suppressive molecules and thereby tumor immune evasion. On the other hand emerging reports indicates that the next generation hallmarks viz., metabolic reprogramming and immune evasion, the two distinct processes are suggested to be fundamentally linked which is yet to be explored. Our concern is, if GRP78 is considered as a connecting link between these two different processes then targeting this triangle would be a promising approach in anticancer drug discovery. Lack of sufficient literature on this aspect represents GRP78 as an under explored target in anti-cancer research. The objective of this review is to provide a concise and integrated information on GRP78 and its association with tumor glycolysis and immune evasion which will revive and draw attention of the researchers to consider GRP78 as a potential drug target for cancer intervention and it also highlights few potential natural products investigated so far as GRP78 inhibitors.
Copyright © 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Carcinogenesis; GRP78 inhibitors; Glucose regulated protein 78; Metabolic reprogramming; Next generation hallmarks; Tumor immune evasion

Mesh:

Substances:

Year:  2020        PMID: 32422159     DOI: 10.1016/j.biochi.2020.05.005

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

Review 1.  Clinical and therapeutic relevance of cancer-associated fibroblasts.

Authors:  Yang Chen; Kathleen M McAndrews; Raghu Kalluri
Journal:  Nat Rev Clin Oncol       Date:  2021-09-06       Impact factor: 66.675

2.  Prognostic value and predictive biomarkers of phenotypes of tumour-associated macrophages in colorectal cancer.

Authors:  Yu Kou; Zhuoqun Li; Qidi Sun; Shengnan Yang; Yunshuai Wang; Chen Hu; Huijie Gu; Huangjian Wang; Hairong Xu; Yan Li; Baowei Han
Journal:  Scand J Immunol       Date:  2022-01-10       Impact factor: 3.889

3.  PDIA2 Bridges Endoplasmic Reticulum Stress and Metabolic Reprogramming During Malignant Transformation of Chronic Colitis.

Authors:  Jie Tao; Lin Yin; Ao Wu; Jiaoli Zhang; Jingpu Zhang; Huichun Shi; Siyuan Liu; Liangfei Niu; Li Xu; Yanling Feng; Shixian Lian; Lei Li; Liyan Zeng; Xianmin Meng; Xiaohui Zhou; Tiefu Liu; Lijun Zhang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

4.  An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data.

Authors:  Yanbiao Liu; Zining Jin; Xinmiao Yu; Ang Zheng; Feng Jin; Xu Wang
Journal:  PeerJ       Date:  2022-08-31       Impact factor: 3.061

5.  EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress.

Authors:  Wenbing Wu; Hui Gou; Bin Xiang; Ruiman Geng; Jingying Dong; Xiaolong Yang; Dan Chen; Rongyang Dai; Lihong Chen; Ji Liu
Journal:  J Oncol       Date:  2022-09-13       Impact factor: 4.501

6.  A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis.

Authors:  Yuanyuan Yan; Miao He; Lin Zhao; Huizhe Wu; Yanyun Zhao; Li Han; Binbin Wei; Dongman Ye; Xuemei Lv; Yan Wang; Weifan Yao; Haishan Zhao; Bo Chen; Zining Jin; Jian Wen; Yan Zhu; Tao Yu; Feng Jin; Minjie Wei
Journal:  Cell Death Differ       Date:  2022-03-17       Impact factor: 12.067

Review 7.  Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.

Authors:  Hui Xu; Chenxi Cao; Yuqing Ren; Siyuan Weng; Long Liu; Chunguang Guo; Libo Wang; Xinwei Han; Jianzhuang Ren; Zaoqu Liu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.